GEOMX Trademark

Trademark Overview


On Wednesday, May 9, 2018, a trademark application was filed for GEOMX with the United States Patent and Trademark Office. The USPTO has given the GEOMX trademark a serial number of 87914539. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, June 16, 2022. This trademark is owned by NanoString Technologies, Inc.. The GEOMX trademark is filed in the Pharmaceutical Products category with the following description:

diagnostic reagents and instruments for medical or veterinary use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; diagnostic reagent kits comprising primarily of diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; chemical reagents for medical use; reagents for medical or veterinary use containing antibodies and nucleic acids; diagnostic test kits for medical use comprising primarily reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical or veterinary diagnostic kits comprising medical or veterinary diagnostic reagents for use in detecting the presence of analytes in samples and identifying sample type, and equipment, namely, medi...
geomx

General Information


Serial Number87914539
Word MarkGEOMX
Filing DateWednesday, May 9, 2018
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, June 16, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 11, 2018

Trademark Statements


Goods and Servicesdiagnostic reagents and instruments for medical or veterinary use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; diagnostic reagent kits comprising primarily of diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; chemical reagents for medical use; reagents for medical or veterinary use containing antibodies and nucleic acids; diagnostic test kits for medical use comprising primarily reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical or veterinary diagnostic kits comprising medical or veterinary diagnostic reagents for use in detecting the presence of analytes in samples and identifying sample type, and equipment, namely, medical diagnostic immuno-assays for screening samples detecting the presence of analytes in samples and identifying sample type, sold as a unit with instructional manuals; diagnostic preparations in the nature of antibodies, for medical and veterinary purposes; reagents and diagnostic reagents for medical or veterinary purposes; diagnostic preparations in the nature of in situ hybridization probes, for medical and veterinary purposes; medical or veterinary diagnostic reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; multiparameter quantitative detection and analysis products and technology for diagnostics for a variety of uses in health care, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents and assays for testing of body fluids or tissue; kits consisting primarily of medical or veterinary diagnostic reagents and assays for testing of body fluids or tissue; reagents in the form of cell markers and molecule markers including antibodies and nucleic acids for medical or veterinary purposes; medical diagnostic reagents for use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents for use relating to molecular identification and digital quantification; medical diagnostic reagents containing antibodies and nucleic acids; medical diagnostic reagents for use in the fields of cancer, neurology and infectious disease; medical diagnostic reagents for immuno-histochemistry detection and in situ-hybridization detection; medical diagnostic reagents for use relating to molecular identification and digital quantification

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 18, 2018
Primary Code005
First Use Anywhere DateWednesday, September 5, 2018
First Use In Commerce DateWednesday, September 5, 2018

Trademark Owner History


Party NameNanoString Technologies, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Party NameNanoString Technologies, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Trademark Events


Event DateEvent Description
Saturday, May 12, 2018NEW APPLICATION ENTERED
Friday, May 18, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 30, 2018ASSIGNED TO EXAMINER
Friday, August 31, 2018PRIORITY ACTION WRITTEN
Friday, August 31, 2018PRIORITY ACTION E-MAILED
Friday, August 31, 2018NOTIFICATION OF PRIORITY ACTION E-MAILED
Sunday, October 14, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, October 14, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 15, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 18, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 2, 2018ASSIGNED TO LIE
Friday, November 2, 2018LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, November 21, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 11, 2018PUBLISHED FOR OPPOSITION
Tuesday, December 11, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 5, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 5, 2019SOU EXTENSION 1 FILED
Thursday, August 15, 2019TEAS PETITION TO REVIVE RECEIVED
Thursday, August 15, 2019PETITION TO REVIVE-GRANTED
Thursday, August 15, 2019SOU EXTENSION RECEIVED WITH TEAS PETITION
Thursday, August 15, 2019NOTICE OF REVIVAL - E-MAILED
Wednesday, October 2, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 2, 2019SOU EXTENSION 1 GRANTED
Thursday, October 3, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2019TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, October 23, 2019DIVISIONAL REQUEST RECEIVED
Friday, October 25, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 28, 2019DIVISIONAL PROCESSING COMPLETE
Tuesday, October 29, 2019CORRECTED NOA E-MAILED
Thursday, January 30, 2020SOU TEAS EXTENSION RECEIVED
Thursday, January 30, 2020SOU EXTENSION 2 FILED
Thursday, January 30, 2020SOU EXTENSION 2 GRANTED
Saturday, February 1, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 20, 2020SOU TEAS EXTENSION RECEIVED
Monday, July 20, 2020SOU EXTENSION 3 FILED
Monday, July 20, 2020SOU EXTENSION 3 GRANTED
Wednesday, July 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 20, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, January 20, 2021SOU EXTENSION 4 FILED
Wednesday, January 20, 2021SOU EXTENSION 4 GRANTED
Friday, January 22, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 5, 2021TEAS STATEMENT OF USE RECEIVED
Thursday, August 5, 2021SOU TEAS EXTENSION RECEIVED
Thursday, August 5, 2021SOU EXTENSION 5 FILED
Thursday, August 5, 2021USE AMENDMENT FILED
Monday, August 16, 2021SOU EXTENSION 5 GRANTED
Monday, August 16, 2021STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 17, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 19, 2021ASSIGNED TO EXAMINER
Monday, August 30, 2021ASSIGNED TO EXAMINER
Friday, December 3, 2021SU - NON-FINAL ACTION - WRITTEN
Friday, December 3, 2021NON-FINAL ACTION E-MAILED
Friday, December 3, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 16, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, June 16, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND